What Is Tirzepatide? GIP-Backbone Dual Agonist: Structure, Receptor Balance and Research

Built on a GIP backbone, tirzepatide is a synthetic 39-residue peptide that switches on two receptors at once: the one for glucose-dependent insulinotropic polypeptide and the GLP-1 receptor. It was the first dual incretin agonist to be taken through a large development programme, and the "twincretin" nickname stuck. For a laboratory, its value is as a tool compound — the standard way to ask what changes when one ligand, rather than a pair of separate ligands, occupies both incretin receptors. Our material ships as lyophilized powder in sealed vials and is intended solely for in-vitro and preclinical study.

Clinical data in humans relate to the approved medicine built on this molecule. Those results describe a regulated pharmaceutical rather than the reference material described here, and nothing on this page constitutes a protocol for human use.

Tirzepatide defined

Tirzepatide is an unbranched 39-amino-acid chain; a C20 fatty diacid hangs off it by way of a glutamate linker plus two short ethoxy-type spacers. A common misreading is to picture a GLP-1 molecule with GIP activity bolted on. The history runs the other way: the chemists started from native GIP and introduced substitutions until GLP-1 receptor activity appeared. That origin shows up in the data. At its home receptor, GIPR, tirzepatide binds with near-native affinity and high potency; at GLP-1R it is noticeably weaker than a purpose-built analogue like semaglutide. The correct label is therefore an unbalanced dual agonist, with the weighting tilted toward GIP.

Design and structure

• Scaffold. Derived from GIP(1-39) and 39 residues long — appreciably longer than the 31-residue GLP-1 analogues in the same collection.
• Aib at positions 2 and 13. The Aib (α-aminoisobutyric acid) in position 2 blocks cutting by DPP-4; the one in position 13 adds further helical rigidity and, according to published structure–activity work, contributes to how activity is split between the two receptors.
• C20 fatty diacid on Lys20. The lipid is longer than the one on semaglutide and is attached through a γ-Glu residue followed by two AEEA spacers; it lets the molecule bind albumin reversibly, which underlies the extended circulation seen in pharmacokinetic reports.
• Amidated C-terminus. With the terminal carboxyl converted to an amide, one negative charge disappears and carboxypeptidases find the chain a poorer substrate.

Key identifiers: CAS 2023788-19-2, empirical formula C225H348N48O68, molecular weight 4813.45 Da. That puts it near 4.8 kDa, toward the top of the incretin mass range, and the difference compared with semaglutide is large enough that a mass-spectrometry identity test separates the two without ambiguity.

Mechanism of action

Mechanistically, everything hinges on hitting two Gs-coupled class B GPCRs with the same molecule. On pancreatic beta cells, activating the GLP-1 receptor raises intracellular cAMP and potentiates insulin secretion, but only when glucose is elevated. GIPR stimulation produces a similar beta-cell response, yet its receptor is also expressed in places GLP-1R signalling does not reach. Fat cells carry GIPR, and studies there describe changes in lipid storage capacity and adipose perfusion; alpha cells carry it too, and reports indicate GIP can shift glucagon output depending on the prevailing glucose level.

In-vitro papers keep returning to two features. One is biased signalling. Compared with native GLP-1, tirzepatide is reported to pull in very little beta-arrestin at GLP-1R, so fewer receptors are internalised and the cAMP signal lasts longer; several authors have proposed this as part of the reason it performs so strongly in vivo. The other is the imbalance between receptors. Because GIPR responds at lower concentrations than GLP-1R, low receptor occupancy gives mostly a GIP-type response, and the GLP-1 contribution only grows as concentrations rise. A dose–response study that ignores this ends up fitting a single curve to what are really two overlapping pharmacologies.

Research applications

• Cell and receptor work. Binding and cAMP readouts in cell lines carrying human GIPR or GLP-1R, arrestin-recruitment assays, live imaging of how receptors traffic, and experiments using receptor knockouts or selective antagonists to attribute each response to one receptor or the other.
• Rodent work. Diet-induced obese animals showing reduced feeding and shifts in fat mass, hepatic fat studies, experiments on thermogenesis in brown fat, and knockout lines used to decide whether an effect runs through GIPR or GLP-1R. The size of the GIP contribution is still argued over in these papers and is best treated as an open question.
• Clinical programmes for the licensed drug. Big randomised trials in obesity and in type 2 diabetes, plus published studies in obstructive sleep apnoea and in HFpEF (heart failure where ejection fraction is preserved). These concern an authorised medicine used under prescription and say nothing about research-grade powder.

For bench work this has a direct consequence. The two receptor arms can be pulled apart with the right controls, so a well-designed tirzepatide study carries at least one comparator that acts on only one receptor. Running a selective GLP-1 receptor agonist in parallel lets you subtract the GLP-1 share of a response; a GIPR-selective agonist or antagonist arm then tells you what is left. Data from tirzepatide on its own rarely allow a receptor to be named — and that missing control is the weakness reviewers most often find in dual-agonist papers.

One open question drives a good deal of today's mechanistic work: is agonism or antagonism at the GIP receptor the metabolically beneficial direction? Both approaches have shown activity in preclinical models, and resolving that apparent contradiction is an active line of research.

Watch the species, too. GIPR is less conserved between rodents and humans than GLP-1R, so a potency ratio measured on mouse or rat receptors may not carry over to the human one. When reading tirzepatide papers, note which orthologue each assay used, and regard any rodent-to-human extrapolation of the GIP component as something still to be tested.

Available formats and vial sizes

Large vials (60 mg, 100 mg) suit multi-arm animal protocols and screening panels, where supplying every group from a single lot takes batch variation out of the analysis. Small receptor studies are usually better served by the 10 mg vial. The tirzepatide product page lists current sizes and prices; related compounds are grouped in the GLP-1 and incretin collection.

Reconstitution and storage at the bench

Working out the concentration is simple arithmetic. Bring a 30 mg vial to a final volume of 3 mL with bacteriostatic water and you have 10 mg/mL, i.e. 10,000 mcg/mL; each 0.05 mL then holds 500 mcg. Run the diluent slowly down the inside of the glass, allow the cake to go into solution on its own rather than shaking it, and confirm the liquid is fully clear before you draw from it — a lipidated peptide of this size forms visible aggregates quickly when agitated.

Unopened lyophilized vials belong at −20 °C, dry and in the dark. Once reconstituted, hold the solution at 2–8 °C and finish it within the planned study window. Tirzepatide tends to be bought in large vials, which makes splitting the solution into single-use aliquots straight after reconstitution more important than it is for small peptides; every additional freeze-thaw cycle applied to a common stock costs measurable purity. The full procedure is in our reconstitution guide.

Purity and reading the certificate of analysis

Expect the certificate to show an HPLC chromatogram and the area-percent of the main peak, an observed mass compared against the theoretical 4813.45 Da, the net peptide content, the lot number and when the analysis was run. With a 39-mer made by solid-phase synthesis, the impurities themselves tell a story: truncated (deletion) sequences and incompletely deprotected species come off the column close to the main peak. A flat baseline and well-separated shoulders say more about how the batch was made than one headline purity figure does. Make sure the certificate's lot matches the lot printed on the vial — see how to read a peptide COA.

Regulatory position

As a finished pharmaceutical, tirzepatide is authorised as a prescription-only medicine in the EU, the United States and elsewhere. The research-grade substance sold here is a laboratory reference chemical: for research use only, not for human consumption, and never a replacement for a prescribed medicine.

Related compounds and comparisons

The natural points of comparison are semaglutide, which acts on one receptor, and retatrutide, which acts on three; both pairings are covered in semaglutide vs tirzepatide and retatrutide vs tirzepatide. Dual agonists that bring in the glucagon receptor instead are covered under survodutide.

Matching catalogue section: GLP-1 & Incretin Peptides